Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNCA NYSE:NAVB NASDAQ:PXMD NASDAQ:SYRS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNCAGenocea Biosciences$0.00$0.00▼$0.00$6K1.6183,499 shsN/ANAVBNavidea Biopharmaceuticals$0.00$0.00▼$0.05$10K1.767,146 shsN/APXMDPaxMedica$0.00$0.00$0.00▼$0.02$6K-0.994,598 shsN/ASYRSSyros Pharmaceuticals$0.00$0.00$0.00▼$0.04$3K1.3118,496 shs16,487 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNCAGenocea Biosciences0.00%0.00%0.00%0.00%0.00%NAVBNavidea Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%PXMDPaxMedica0.00%0.00%0.00%0.00%+400.00%SYRSSyros Pharmaceuticals0.00%0.00%-75.00%-50.00%-99.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNCAGenocea Biosciences$0.00$0.00▼$0.00$6K1.6183,499 shsN/ANAVBNavidea Biopharmaceuticals$0.00$0.00▼$0.05$10K1.767,146 shsN/APXMDPaxMedica$0.00$0.00$0.00▼$0.02$6K-0.994,598 shsN/ASYRSSyros Pharmaceuticals$0.00$0.00$0.00▼$0.04$3K1.3118,496 shs16,487 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNCAGenocea Biosciences0.00%0.00%0.00%0.00%0.00%NAVBNavidea Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%PXMDPaxMedica0.00%0.00%0.00%0.00%+400.00%SYRSSyros Pharmaceuticals0.00%0.00%-75.00%-50.00%-99.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNCAGenocea Biosciences 0.00N/AN/AN/ANAVBNavidea Biopharmaceuticals 0.00N/AN/AN/APXMDPaxMedica 0.00N/AN/AN/ASYRSSyros Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNCAGenocea Biosciences$1.91M0.00N/AN/A$0.47 per share0.00NAVBNavidea Biopharmaceuticals$8.13K0.00N/AN/AN/ANaNPXMDPaxMedicaN/AN/AN/AN/A$0.46 per shareN/ASYRSSyros Pharmaceuticals$386K0.01N/AN/A$0.79 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNCAGenocea Biosciences-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/ANAVBNavidea Biopharmaceuticals-$15.18M-$0.21N/AN/AN/AN/AN/AN/AN/APXMDPaxMedica-$18.29M-$6.09N/AN/AN/AN/A-3,167.89%-560.35%9/2/2026 (Estimated)SYRSSyros Pharmaceuticals-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%7/29/2026 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGNCAGenocea BiosciencesN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/APXMDPaxMedicaN/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNCAGenocea Biosciences0.241.351.35NAVBNavidea BiopharmaceuticalsN/AN/AN/APXMDPaxMedicaN/A0.380.38SYRSSyros PharmaceuticalsN/A2.252.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNCAGenocea Biosciences0.64%NAVBNavidea Biopharmaceuticals0.01%PXMDPaxMedica4.90%SYRSSyros Pharmaceuticals91.47%Insider OwnershipCompanyInsider OwnershipGNCAGenocea Biosciences1.61%NAVBNavidea Biopharmaceuticals43.68%PXMDPaxMedica1.00%SYRSSyros Pharmaceuticals12.26%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNCAGenocea Biosciences7058.73 million57.79 millionNot OptionableNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionNo DataPXMDPaxMedica211.31 million11.20 millionNot OptionableSYRSSyros Pharmaceuticals12026.83 million23.54 millionNo DataSYRS, NAVB, GNCA, and PXMD HeadlinesRecent News About These CompaniesRege Nephro buys Tamibarotene-related assets from Syros PharmaceuticalsApril 15, 2025 | msn.comSyros Pharmaceuticals trading resumesMarch 1, 2025 | markets.businessinsider.comSyros Pharmaceuticals Plans to Wind Down OperationsMarch 1, 2025 | marketwatch.comSyros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stockMarch 1, 2025 | markets.businessinsider.comSyros Announces Voluntary Delisting from Nasdaq and SEC DeregistrationFebruary 28, 2025 | businesswire.comSyros Pharmaceuticals stock hits 52-week low at $0.18 amid steep declineJanuary 29, 2025 | msn.comSyros Pharmaceuticals Inc (SYRS) Stock Price Reaches $0.22: What Factors Are Influencing This Level?January 18, 2025 | bovnews.comBWhat’s Causing Syros Pharmaceuticals Inc (SYRS) Stock’s -96.35% Drop Over the Last Six Months?January 16, 2025 | bovnews.comBSYRS’s Latest Surge: What’s Behind the Spike?January 6, 2025 | bovnews.comBThe SYRS Conundrum: Why Syros Pharmaceuticals Inc’s Stock Is Making Headlines AgainJanuary 2, 2025 | bovnews.comBAnalysts Predict a $15 Target for Syros Pharmaceuticals Inc (SYRS) Stock—What Could Drive It There?December 31, 2024 | bovnews.comBSyros Pharmaceuticals Inc (SYRS) Stock: More Resilient Than It AppearsDecember 27, 2024 | bovnews.comBSyros Pharmaceuticals Inc (SYRS) Stock Dive: The Hidden Causes RevealedDecember 26, 2024 | bovnews.comBWhat’s Fueling Syros Pharmaceuticals Inc (SYRS) Stock’s -94.59% Loss Below Its 200-Day SMA?December 14, 2024 | bovnews.comBSyros Pharmaceuticals Inc (SYRS) Stock Settles at $0.24: What’s Contributing to This Price Point?December 7, 2024 | bovnews.comBWhy Did Syros Pharmaceuticals Inc (SYRS) Stock Plunge -1.67% Last Week?December 5, 2024 | bovnews.comBNancy A. Simonian Sells 37,070 Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) StockDecember 5, 2024 | insidertrades.comSyros Pharmaceuticals Inc (SYRS) Stock Rated Buy by H.C. WainwrightDecember 2, 2024 | bovnews.comBWhy Is Syros Pharmaceuticals Inc (SYRS) Stock Lagging Behind -84.72% from Its 50-Day SMA?November 29, 2024 | bovnews.comBSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Sells $36,372.51 in StockNovember 28, 2024 | insidertrades.comNew MarketBeat Followers Over TimeSYRS, NAVB, GNCA, and PXMD Company DescriptionsGenocea Biosciences NASDAQ:GNCAGenocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.Navidea Biopharmaceuticals NYSE:NAVBNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.PaxMedica NASDAQ:PXMD$0.0005 0.00 (0.00%) As of 07/2/2026PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.Syros Pharmaceuticals NASDAQ:SYRS$0.0001 0.00 (0.00%) As of 07/2/2026 03:01 PM EasternSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
